Therefore, our results demonstrate that an early increase in TNF-α after the first Ate/Bev treatment could be an important prognostic marker for survival in HCC patients undergoing this therapy, suggesting that continuing Ate/Bev therapy could be beneficial. This evidence concerns the gene TNF and hepatocellular carcinoma.